Nitinotes Completes $10.1 Million Series B Funding Round

This significant milestone brings the total funds raised by Nitinotes to $23.6 million.

The newly acquired capital will be strategically allocated to complete our EU clinical studies, secure the CE mark, and prepare for EU market entry. Additionally, the funding will expedite the development of our next-generation Endozip product.

We sincerely thank our investors for their steadfast support and commitment, particularly during these challenging times. This funding serves as a pivotal step in our ongoing efforts to innovate and transform the field of obesity treatment through our groundbreaking ESG procedure.